Embattled Salix hires bankers to weigh a potential sale

Salix Pharmaceuticals ($SLXP) has taken a step toward a potential sale. Haunted by an inventory snafu and a C-suite shakeup, the company was already facing investor pressure to look for bidders once its supply issues were resolved. Now, Salix has tapped Crestview Partners to "explore options" as it hunts for a new CEO. No decision is expected until after that person comes on board, however. Report

Suggested Articles

Novartis is joining a group of drugmakers already advertising cancer treatments on TV with the launch of its Piqray campaign. 

With Johnson & Johnson battling talc and opioid lawsuits and now a Risperdal verdict, is the brand facing a decline?

Transparency in drug pricing sounds like a great idea, but a new study finds that almost none of the state laws provide real price insights.